Boston Scientific's $14.7B Penumbra Acquisition Faces FTC Scrutiny, Stock Consideration Value Drops

summarizeSummary

Boston Scientific filed an amended S-4 for its approximately $14.71 billion acquisition of Penumbra, revealing a Second Request from the FTC for regulatory approval and detailing Boston Scientific's commitments to overcome antitrust hurdles.

check_boxKey Events

• Major Acquisition Update

  Boston Scientific is proceeding with its approximately $14.71 billion acquisition of Penumbra, as detailed in this amended S-4 filing.

• FTC Issues Second Request

  The Federal Trade Commission (FTC) has issued a Second Request for information, indicating an extended and more in-depth regulatory review of the merger.

• Regulatory Commitments

  Boston Scientific has committed to litigate against any regulatory challenges and, if necessary, divest assets generating up to $300 million in revenue for the year ended December 31, 2025, to secure antitrust approval. A $900 million reverse termination fee is stipulated for regulatory failure.

• Stock Consideration Value Decline

  The value of the stock consideration for Penumbra shareholders has decreased to $267.83 per share as of March 27, 2026, from the initial implied value of $374.00 per share at the merger announcement, reflecting a decline in Boston Scientific's stock price.

auto_awesomeAnalysis

This amended S-4 filing provides critical updates on Boston Scientific's approximately $14.71 billion acquisition of Penumbra, a significant strategic move to expand its medical technology portfolio. The most material new information is the Federal Trade Commission's issuance of a Second Request for additional information, indicating heightened regulatory scrutiny and potential for delays or required divestitures. Boston Scientific's commitment to litigate and divest assets up to $300 million in revenue, alongside a $900 million reverse termination fee for regulatory failure, highlights the challenges but also the company's determination to complete the deal. For Penumbra shareholders, the value of the stock consideration has notably decreased to $267.83 per share (as of March 27, 2026) from the initial implied value of $374.00 per share at the merger announcement, reflecting Boston Scientific's stock trading near its 52-week lows. The intention of Penumbra's CEO to join the Boston Scientific board and elect stock consideration signals confidence in the long-term prospects of the combined entity, despite the current market and regulatory headwinds. Investors should closely monitor the regulatory approval process and its potential impact on the deal's timeline and final terms.